N/A N=92 Vitamin D Deficiency, Insulin Resistance and FGF-23
Vitamin D Deficiency
Primary: Fibroblast Growth Factor 23 (FGF23) After 12 Weeks of Weekly Ergocalciferol 50000 Units — 74; 39 pg/mL — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=161 ST-segment Elevation as an AF Endophenotype
Atrial Fibrillation
Primary: ST Segment Elevation ≥ 1.5 mm in the Right Precordial Leads (V1-V3), Either at Baseline or Manifested After Sodium Channel Block With Intravenous Procainamide — 4…
N/A N=46 Improving Information Extraction From EEG on Cerebral Anesthetic Drug Effects
Anesthesia
Primary: Patient State Index (PSI) Comparison, Baseline and Emax — 85.1; 63.1; 63.1; 67.2 index
Phase 3 N=645 A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
Metastatic Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Primary: Progression-free Survival (PFS) — 5.72; 5.39 months
N/A N=100 The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass
Blood Coagulation Disorders
Primary: Amount of Chest Catheter Drainage 24 Hours Postoperatively — 766; 626 mL
Phase 2 N=1 Salvage Ovarian FANG™ Vaccine + Carboplatinum
Stage III Ovarian Cancer · Stage IV Ovarian Cancer
Primary: Time to Progression (TTP)
N/A N=72 Safety and Effectiveness Evaluation of the Device in Achieving Submental Lift
Skin Laxity
Primary: Tissue Lift at the Submental Area Measuring >/= 20 mm2 — 56.9 percentage of participants — p=0.05
Phase 2 N=5 Salvage Ovarian FANG™ Vaccine + Bevacizumab
Stage III Ovarian Cancer · Stage IV Ovarian Cancer
Primary: Time to Progression
Phase 2 N=19 IL1-TRAP, Rilonacept, in Systemic Sclerosis
Scleroderma · Systemic Sclerosis · Diffuse Scleroderma
Primary: Change in 2- Gene Biomarker — -2.67; 0.42 2- gene biomarkers score
Phase 2 N=584 Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression
Depression, Bipolar
Primary: Change From Baseline in the Montgomery-Åsberg Depression Rating Scale Total Score at Week 6 — -11.1; -13.0; -15.1; -13.7 units on a scale — p=0.1292
Phase 3 N=38 Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
Friedreich's Ataxia
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs — 21; 7; 0; 0 participants
Phase 2 N=298 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12 — -0.24; -0.16; -0.35; -0.66 percent of HbA1c — p=.755
Phase 2 N=819 Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 8 — -12.5; -13.4; -14.6 Units on a scale — p=0.2404
Phase 4 N=59 Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?
Workplace Migraine Treatment
Primary: Workplace Productivity and Activity Impairment Scale (WPAI). — 4.15; 2.44 hours — p=0.007
Phase 4 N=413 Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
Dyslipidemia
Primary: Percent Change From Baseline in Non-HDL-C at Week 24: Overall Intent-to-treat (ITT) Analysis — -37.3; -4.7 Percent change — p=<0.0001